Pharmacy Report Archives - Page 37 of 148 - Becker's Hospital Review

IV shortage: CDC shares tips as systems ration | Compounded Mounjaro in limbo: 5 notes | CVS to end infusion services | Ex-hospital CEO charged in 45-count indictment

October 14, 2024 BHR Newsletter 1. CDC issues guidelines for IV, PD fluid shortage Full story 2. Health system strategies to mitigate the IV shortage: What to know Full story 3. 4 hospital expansions worth $1B or more Full story…

IV allocations rise: 6 updates | Pharmacist to lead Ore. hospital | GSK to settle Zantac suits for $2.2B | Hospitals + Milton: 9 notes | 2 Alzheimer's drugs show promise

October 10, 2024 BHR Newsletter 1. Baxter increases IV allocations: 6 shortage updates Full story 2. GSK agrees to settle 80,000 Zantac lawsuits for $2.2B Full story 3. Hospitals and Hurricane Milton: 9 things to know Full story 4. Find…

CMS' $2 drug price list: 5 notes | Pharmacists urge fed'l action as IV shipments resume | Mount Sinai exec joins Eli Lilly | Amazon Pharmacy to expand | GLP-1s may cost Medicare $35B by 2034: CBO

October 9, 2024 BHR Newsletter 1. CMS proposes $2 Medicare drug list: 5 things to know Full story 2. Eli Lilly snags chief AI officer from Mount Sinai Full story 3. Baxter resumes some IV shipments: 5 updates Full story…

FDA sued over Zepbound shortage end | Hospitals urge federal action on IV shortage | 10 notes on hospital pharmacies | CVS to lay off 632 | ChatGPT overprescribes in the ED: Study

October 8, 2024 BHR Newsletter 1. Trade group sues FDA for removing Eli Lilly weight loss drug from shortage list Full story 2. CVS to lay off 632 at Rhode Island headquarters Full story 3. The state of hospital pharmacies…

Hospitals prep for IV fluid shortages | The 73 drugs Baxter's NC site makes | Texas sues PBMs, drugmakers: 5 notes | Hospitals to CMS: Extend prescribing flexibilities | Zepbound shortage ends

October 7, 2024 BHR Newsletter 1. Hospitals prepare for months-long supply disruptions after Helene, port strike Full story 2. The 73 drugs made at Baxter's flooded site Full story 3. Kroger sells specialty pharmacy unit to Elevance Full story 4.…

After $40M settlement, drug trial continues | CMS edits drug price talks | 10 systems seeking pharmacy leaders | La. restricts abortion pill access | Ozempic as an addiction therapy: 4 notes

October 3, 2024 BHR Newsletter 1. CMS tweaks drug price negotiations for 2025 Full story 2. After $40M settlement, Alzheimer's drug under scrutiny as human trials proceed Full story 3. Ozempic as an addiction treatment: 4 notes Full story 4. Don't risk losing to…

CVS' potential breakup: 3 notes | Payer to offer $0 Humira biosimilar: 7 notes | Drug co. pays $40M to settle case | Mass. system exits bankruptcy | An overlooked drug for C. diff

October 2, 2024 BHR Newsletter 1. Patients sue over alleged stomach paralysis linked to Ozempic, Mounjaro Full story 2. Why a CVS breakup may be hard to execute: 3 notes Full story 3. Blue Shield of California's zero-dollar biosimilar strategy:…

CVS board mulls breakup | The future of pharmacy leadership: 7 execs | 1 year post-'pharmageddon': 4 notes | FDA panel votes to restrict cancer drugs | McLaren closes clinics in Walgreens

October 1, 2024 BHR Newsletter 1. UPMC leader: 'We're running out of levers in pharmacy to manage costs' Full story 2. FDA approves drug for thyroid cancer treatment Full story 3. Unionization picks up after 'pharmageddon': 4 things to know…

J&J cancels 340B rebate plan | CVS to lay off 2,900: 4 notes | Main US supplier of IV solutions halts production | FDA approves schizophrenia drug | Systems abandon rigid hierarchies

September 30, 2024 BHR Newsletter 1. J&J to forgo 340B rebate plan implementation Full story 2. Nation's largest supplier of IV solutions temporarily closes amid Helene Full story 3. Investors sour on CVS Health, layoffs announced: 4 notes Full story 4.…

Pfizer withdraws drug: What to know | Mark Cuban's advice to employers | 10 systems seeking pharmacy leaders | Rx delay led to patient death: Study | 5 Ozempic updates

September 26, 2024 BHR Newsletter 1. Pfizer pulls sickle cell disease drug from market Full story 2. Mark Cuban to employers: Save millions with 1 move Full story 3. FDA eyes 1st schizophrenia drug in decades: 5 things to know…